ClinicalTrials.Veeva

Menu

Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis (MIRDIAMUCO)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Completed

Conditions

Cystic Fibrosis

Treatments

Other: miRNAs isolation from blood samples of patients and control

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The aim of our study is to assess miRNAs expression profiles in the circuling blood of patients with cystic fibrosis and highlight "signatures" that could reflect the pulmonary status of patients

Full description

The objective of this project is to study the circulating miRNA profiles in 40 patients with cystic fibrosis (5 samples which are acquired through a secondary use) and 40 healthy individuals to assess whether these biomolecules could be used as markers of the pulmonary disease in cystic fifbosis. Moreover by comparing miRNAs expression level between Cystic fibrosis (CF) patients with severe (n=20) or moderate (n=20) pulmonary impairment, we want to assess whether some of these miRNAs may be used as markers for the severity of CF pulmonary disease. The identification of sensitive and early markers, from a non-invasive sampling could enable more effective and early treatment of CF patients.

Enrollment

80 patients

Sex

All

Ages

12 months to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with Cystic fibrosis (CF) (MIM#219700) who are compound heterozygous or homozygous for CF causing mutations Healthy controls non -smokers and free pulmonary disease

Exclusion criteria

  • Participation or within the exclusion period of other clinicals trials Patients carrying mutations of clinical varying consequences or non CF-causing mutations
  • smokers

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

80 participants in 3 patient groups

Cystic fibrosis Patients
Other group
Treatment:
Other: miRNAs isolation from blood samples of patients and control
Patients without fibrosis cystic
Other group
Treatment:
Other: miRNAs isolation from blood samples of patients and control
Cystic fibrosis Patients (secondary use of samples)
Other group
Treatment:
Other: miRNAs isolation from blood samples of patients and control

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems